Mechanistically, anti-VEGF-A/Ang-2 treatment improved perfusion and reduced leakiness of the remaining tumor vasculature in a phenotype that was associated with increased perivascular accumulation and intra-tumoral infiltration of CD8+ T cells (Kashyap et al. 2020). Here, VEGFA is linked to neoplasm.